# It All Starts With Biology.

Ori is focused on delivering industry-leading biological performance. Together with industry leaders, we've developed a platform specifically designed to match the complexity of life-saving cell and gene therapies. We are working to get the biology right first to meet the unique manufacturing needs of our industry.

# Changing the Status Quo.

Today:

CAR-T therapies are manufactured using manual or semi-automated all-in-one technologies

Biological processes are adapted to fit inflexible manufacturing platforms Ultimately leading to CAR-T processes with sub-optimal biological performance and increased process variability

# The Proof is in the Numbers.

Data from 650 internal and external characterization runs at Ori and LEAP partner sites show the potential of the Ori platform.

### 10 Partners

Ori's LightSpeed Early Access Program (LEAP) includes 5 therapy developers, 4 CDMOs and 1 AMC

### 10 Unique Processes

Different processes including CAR-T, TCR-T, TILs, CD34+ with CAR-M and others on the horizon

### > 650 Runs

Characterization runs completed (in house and at partner sites in NA and UK)

### 50ml to 1L

Flexible operating volume range allows activation, transduction and expansion in one bioreactor

### > 60 Donors / Patients

Testing the platform's ability to address donor and patient variability, showcasing the robustness of system outputs across different starting material

### 12B Cells


Maximum cell yield observed from bioreactor (~170x fold expansion)

# **Ori T-Cell Process Results**.


### **Key Takeaways**

Achieves a maximum cell yield up to **2.5x higher** than a widely used cell expansion system using the same raw materials (cells, cytokines, media, etc.) Consistently reaches 1–2B total cells in 4–6 days and can achieve 10–12B cells in 10 days, maintaining >95% viability Delivers high quality T cells with a desirable T cell memory phenotype and no evidence of exhaustion






CD4/CD8 Ratio



T Cell Exhaustion

CD8+ T Cell Phenotype





### **Ori CD19 CAR-T Process Results**.

### **Key Takeaways**


The Ori platform has delivered more than 2 billion CD19 CAR-T cells in 7 days and up to 4 billion CD19 CAR-T cells in a 9-day process Delivers high quality T cells with a desirable T cell memory phenotype and comparable to the control Produces **functional CAR-T cells** measured by cytokine release and killing assays after co-culturing with NALM6, a CD19-positive cancer cell line








Day 9 Cell Yield




Cytokine Release Assay




# Ori CD19 CAR-T Data - Different MOIs.


### Key Takeaways


**Higher transduction efficiency** was observed in Ori using an updated and optimised protocol compared to Control\* across the tested Multiplicity of Infections (MOI) **Higher yield of CAR-T cells** can be achieved in Ori platform using MOI 0.5 and 0.25 compared to an industry-standard platform (Control) using MOI 1.0. This demonstrates the possibility of **reducing the virus needed** to achieve a target CAR-T yield and ultimately **reducing cost of goods** 






Total CAR-T Yield (Day 8)







### \*A scale-down vessel (10x smaller) of a widely used cell expansion system was used as a control


# Ori CD19 CAR-T Data - Different MOIs.

### **Key Takeaways**


Similar memory phenotype was achieved across Ori and the Control Comparable CD19-specific cytotoxicity and cytokine production when CAR-T from Ori and Control are co-cultured with NALM6 tumor cell line **Vector Copy Number (VCN) <3 copies** per CAR+ cell, across all MOI tested (below the FDA criteria of 5)

Ori

Control




Cytokine Release Assay



[Measured by Ella Automated Immunoassay System]

CD19+ Target (NALM6) CD19- Target (K562) CD19+ Target (K562) CD19- Target (K562) CD19- Target (K562) CD19- Target (K562) CD19- Target (K562) E:T Ratio


[Measured by xCELLigence system]



Killing Assay (MOI: 1)

# **Ori LEAP Partner CAR-T Process Results.**

### **Key Takeaways**



[Measured by ELISpot]



# Manufacturing Brighter Futures.

Ori is a London and Philadelphia-based manufacturing technology company pioneering flexible process discovery with seamless translation and scalable commercialization of cell and gene therapies.

Since 2022, Ori's LEAP program has been giving leading industry partners, like Inceptor Bio, CTMC (a joint venture between Resilience and MD Anderson), an undisclosed commercial CAR-T partner and two publicly listed biotech partner (s), access to Ori's proprietary CGT manufacturing platform prior to commercial launch in 2024. These LEAP partners have been doing feasibility testing of Ori's digitally native manufacturing platform to accelerate their progress toward the scalable production of novel cell therapies.

### Explore How the Ori Platform May Benefit Your Program.

Visit Oribiotech.com